From Hypertransaminasemia to Mucopolysaccharidosis IIIA

Total Page:16

File Type:pdf, Size:1020Kb

From Hypertransaminasemia to Mucopolysaccharidosis IIIA Krawiec et al. Italian Journal of Pediatrics 2014, 40:97 http://www.ijponline.net/content/40/1/97 ITALIAN JOURNAL OF PEDIATRICS CASE REPORT Open Access From hypertransaminasemia to mucopolysaccharidosis IIIA Paulina Krawiec1,2*,Elżbieta Pac-Kożuchowska1,2, Beata Mełges1,2, Agnieszka Mroczkowska-Juchkiewicz1,2, Stanisław Skomra2, Agnieszka Pawłowska-Kamieniak1,2 and Katarzyna Kominek1,2 Abstract Mucopolysaccharidosis type III (MPS III; Sanfilippo syndrome) is a metabolic disorder characterized by the deficiency of a lysosomal enzyme catalyzing the catabolic pathway of heparan sulphate. MPS III presents with progressive mental deterioration, speech delay and behavioural problems with subtle somatic features, which can often lead to misdiagnosis with idiopathic developmental/speech delay, attention deficit/hyperactivity disorder or autism. We report a case of a 5-year-old boy with developmental delay and behaviour problems admitted to the Department of Paediatrics due to chronic hypertransaminasemia. The patient developed normally until the age of 2 years when he was referred to a paediatric neurologist for suspected motor and speech delay. Liver function tests were unexpectedly found elevated at the age of 3.5 years. Physical examination revealed obesity, mildly coarse facial features and stocky hands. He showed mental retardation and mild motor delay. The clinical picture strongly suggested mucopolysaccharidosis. The diagnosis of MPS IIIA was confirmed by decreased activity of heparan N-sulfatase in leucocytes. Conclusion: We strongly recommend screening for MPS III in children with severe behavioural abnormalities with hyperactivity, psychomotor or speech deterioration and failure to achieve early developmental milestones particularly with facial dysmorphism. Keywords: Mucopolysaccharidosis type IIIA, Sanfilippo syndrome, Hypertransaminasemia Background idiopathic developmental/speech delay, attention deficit/ Mucopolysaccharidosis (MPS) type III, also known as Sanfi- hyperactivity disorder (ADHD) or autism spectrum disor- lippo syndrome, is an autosomal recessive metabolic dis- ders [2]. order characterized by the deficiency of a lysosomal enzyme We report a rare case of a boy with unexpected MPS IIIA catalyzing the catabolic pathway of glycosaminoglycan diagnosis to highlight the importance of paediatric history (GAG) - heparan sulfate. Based on the deficiency of a spe- and physical examination for the diagnostic process and to cific enzyme in the degradation of heparan sulphate, four indicate that patients with metabolic disorders may develop different subtypes of MPS III are distinguished, i.e. MPS III any other chronic diseases. A (heparan N-sulfatase), MPS III B (α-N-acetylglucosamini- dase), MPS III C (heparan acetyl-CoA: alpha-glucosaminide Case report N-acetyltransferase) and MPS III D (N-acetylglucosamine 6- A 5-year-old boy with developmental delay was admitted sulfatase) [1,2]. to the hospital for persistent hypertransaminasemia of MPS III presents with progressive mental deterioration, 18 months’ duration. speech delay and behavioural problems with only subtle The boy was born at term after the uncomplicated preg- somatic features, which can often lead to misdiagnosis with nancy by caesarean section due to the ultrasound con- firmed large foetus weight and dehiscence of the pubic * Correspondence: [email protected] symphysis. His birth weight was 4,570 g and birth length 1 Department of Paediatrics, Medical University of Lublin, Racławickie 1, was 59 cm. At the first minute after birth the Apgar score 20-059 Lublin, Poland 2Department of Paediatrics, Children’s University Hospital in Lublin, Gębali 6, was 10. No neonatal problems were reported. The boy was 20-093 Lublin, Poland the second child in the family and had the older healthy © 2014 Krawiec et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Krawiec et al. Italian Journal of Pediatrics 2014, 40:97 Page 2 of 5 http://www.ijponline.net/content/40/1/97 sister. The parents were healthy and non-consanguineous. Liver function tests were unexpectedly found to be ele- However, his mother had the history of 2 miscarriages in vated at the age 3.5 years when he was hospitalized due to the first trimester. pneumonia. Alanine aminotransferase (ALT) was 144 U/L According to his parents, the child’s development was (normal <29 U/L) and aspartate aminotransferase (AST) normal until the age of 2 years. Head control was was 90 U/L (normal <36 U/L). Thereafter, elevated ALT and achieved by the 3rd month of life, sitting without assist- AST were observed in follow-up laboratory tests. ance in the 6th month of life and walking in the 9th On admission to our Department his weight was 36.3 kg month of life. However, he began using single, simple (> > 97th percentile) and height 115 cm (75th percentile). words (i.e. mum, dad) at the age of 18 months. Toilet The Cole’s index was 181.5% and the body mass index was control was achieved at 3 years of age. Since the 2nd year 27.4 kg/m2 (>>97th percentile). of life progressive psychomotor developmental delay, On physical examination, the boy appeared to have restlessness and impulsivity with hyperactivity became mildly coarse facial features, the slightly depressed nasal apparent, therefore he was referred to a paediatric neur- bridge, prominent eyebrows, low set ears, malocclusion, ologist. About the age of 5 years lack of speech and toi- full cheeks, wiry and dry hair and the short neck (Figure 1). let control were noticed. The boy had excessive lumbosacral lordosis, genu valga The clinical history revealed recurrent upper respira- (knock-knee deformity) and varus feet. He had broad-base tory tract infections and recurrent diarrhoea. At present, gait with anteversion. His hands were stocky with short his stools are rather constipated. He had adenotomy at fingers. The liver and the spleen were not palpable. the age of 2 years. Since birth, the boy had the tendency The boy showed mental retardation and mild motor to excessive weight. delay. His speech was limited to incomprehensible Figure 1 Dysmorphic features of our patient. Facial dysmorphism (coarse facial features, the slightly depressed nasal bridge, prominent eyebrows, low set ears, malocclusion, full cheeks, wiry and dry hair and the short neck) and skeletal symptoms (genu valga, varus feet, and stocky hands) seen in our patient. Krawiec et al. Italian Journal of Pediatrics 2014, 40:97 Page 3 of 5 http://www.ijponline.net/content/40/1/97 sounds. The boy presented anxious and restless Table 1 Laboratory results of our patient behaviour. Parameter Result Reference range The clinical picture strongly suggested mucopolysacchari- ALT [U/L] 144 <29 dosis. The daily urinary glycosaminoglycans (GAGs) excre- AST [U/L] 73 <36 tion was 895 mg GAG/g creatinine, i.e. elevated compared Bilirubin [mg/dL] 1.7 1.5 to the normal reference level (<88 mg GAG/g creatinine). Elevated GAGs were identified as chondroitin sulphate and GGT [U/L] 34 <29 heparan sulphate, which suggested mucopolysaccharidosis CK [U/L] 98 <149 III. To confirm the diagnosis and to determine the type of IgG [mg/dL] 521 504-1464 MPS the lysosomal enzyme activity was assessed in Total cholesterol [mg/dL] 111 <170 leucocytes. Heparan N-sulfatase activity was decreased Triglyceride [mg/dL] 58 <75 (1.29 nmol/mg protein/18 h) compared to the normal refer- HBs-Antigen Negative Negative ence range (4.1 ± 1.4 nmol/mg protein/18 h). The activities of other lysosomal enzymes i.e. α-iduronidase, α-N- Anti-HCV antibodies Negative Negative acetylglucosaminidase, N-acetyl-transferase, glucosamine Anti-EBV antibodies Negative Negative sulfatase, galactosamine sulfatase, β-glucoronidase, arylsul- Anti-CMV antibodies Negative Negative fatase and iduronide sulfatase were within normal limits. Lysosomal acid lipase [pmol/punch/hr] 0.61 0.37-2.3 The diagnosis of mucopolysaccharydosis III type A was α-1-antitrypsin [g/L] 1.3 0.9-2.0 confirmed. Ceruloplasmin [g/L] 0.3 0.15-0.3 Moreover, laboratory results revealed hypertransaminase- mia with slightly elevated γ-glutamyltranspeptydase. De- Serum copper [ug/L] 1106 900-1900 tailed diagnostic examinations were performed to determine 24-hour urinary copper [ug/24 h] <10 <60 the cause of hypertransaminasemia. Based on the serological tests viral hepatitis caused by hepatitis B virus (HBV), hepa- titis C virus (HCV), cytomegalovirus (CMV) and Ebstein – progression of symptoms and shorter survival than the Barr virus (EBV) were excluded. The serum level of creatine other subtypes [1]. kinase, total immunoglobulin G (IgG), α1-antitrypsin, lyso- The majority of children with MPS IIIA were born somal acid lipase, ceruloplasmin, copper and 24-hour urin- after uneventful pregnancies [1,3]. Buhrman et al. found ary copper were within the normal range. Thus, muscular that the most common pregnancy complication was cae- dystrophy, autoimmune hepatitis, α1-antitrypsin deficiency, sarean section due to failure to progress, macrocephaly lysosomal acid lipase deficiency and Wilson’sdiseasewe and breech position, suggesting that the GAGs storage excluded. Table 1 presents the laboratory results of our already occur before birth, which was also found in our patient. patient’s perinatal history [4]. On the abdominal ultrasound examination, the bright Interestingly, Meyer et al. noticed a high number of mis- liver echo pattern was found; the liver and spleen were carriages in mothers of children with MPS IIIA (29%). The not enlarged. above data need to be interpreted with caution as the inci- Chronic hypertransaminasemia in our patient might dence of miscarriages is age-dependent and the exact age of be related to mucopolysaccharidosis or result from coex- mothers at the time of miscarriage was unknown. However, isting non-alcoholic steatohepatitis (NASH).
Recommended publications
  • Pathophysiology of Mucopolysaccharidosis
    Pathophysiology of Mucopolysaccharidosis Dr. Christina Lampe, MD The Center for Rare Diseases, Clinics for Pediatric and Adolescent Medicine Helios Dr. Horst Schmidt Kliniken, Wiesbaden, Germany Inborn Errors of Metabolism today - more than 500 diseases (~10 % of the known genetic diseases) 5000 genetic diseases - all areas of metabolism involved - vast majority are recessive conditions 500 metabolic disorders - individually rare or very rare - overall frequency around 1:800 50 LSD (similar to Down syndrome) LSDs: 1: 5.000 live births MPS: 1: 25.000 live births 7 MPS understanding of pathophysiology and early diagnosis leading to successful therapy for several conditions The Lysosomal Diseases (LSD) TAY SACHS DIS. 4% WOLMAN DIS. ASPARTYLGLUCOSAMINURIA SIALIC ACID DIS. SIALIDOSIS CYSTINOSIS 4% SANDHOFF DIS. 2% FABRY DIS. 7% POMPE 5% NIEMANN PICK C 4% GAUCHER DIS. 14% Mucopolysaccharidosis NIEMANN PICK A-B 3% MULTIPLE SULPH. DEF. Mucolipidosis MUCOLIPIDOSIS I-II 2% Sphingolipidosis MPSVII Oligosaccharidosis GM1 GANGLIOSIDOSIS 2% MPSVI Neuronale Ceroid Lipofuszinois KRABBE DIS. 5% MPSIVA others MPSIII D A-MANNOSIDOSIS MPSIII C MPSIIIB METACHROMATIC LEUKOD. 8% MPS 34% MPSIIIA MPSI MPSII Initial Description of MPS Charles Hunter, 1917: “A Rare Disease in Two Brothers” brothers: 10 and 8 years hearing loss dwarfism macrocephaly cardiomegaly umbilical hernia joint contractures skeletal dysplasia death at the age of 11 and 16 years Description of the MPS Types... M. Hunter - MPS II (1917) M. Hurler - MPS I (1919) M. Morquio - MPS IV (1929) M. Sanfilippo - MPS III (1963) M. Maroteaux-Lamy - MPS IV (1963) M. Sly - MPS VII (1969) M. Scheie - MPS I (MPS V) (1968) M. Natowicz - MPS IX (1996) The Lysosome Lysosomes are..
    [Show full text]
  • Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment
    International Journal of Molecular Sciences Review Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment Francesca D’Avanzo 1,2 , Laura Rigon 2,3 , Alessandra Zanetti 1,2 and Rosella Tomanin 1,2,* 1 Laboratory of Diagnosis and Therapy of Lysosomal Disorders, Department of Women’s and Children ‘s Health, University of Padova, Via Giustiniani 3, 35128 Padova, Italy; [email protected] (F.D.); [email protected] (A.Z.) 2 Fondazione Istituto di Ricerca Pediatrica “Città della Speranza”, Corso Stati Uniti 4, 35127 Padova, Italy; [email protected] 3 Molecular Developmental Biology, Life & Medical Science Institute (LIMES), University of Bonn, 53115 Bonn, Germany * Correspondence: [email protected] Received: 17 January 2020; Accepted: 11 February 2020; Published: 13 February 2020 Abstract: Mucopolysaccharidosis type II (MPS II, Hunter syndrome) was first described by Dr. Charles Hunter in 1917. Since then, about one hundred years have passed and Hunter syndrome, although at first neglected for a few decades and afterwards mistaken for a long time for the similar disorder Hurler syndrome, has been clearly distinguished as a specific disease since 1978, when the distinct genetic causes of the two disorders were finally identified. MPS II is a rare genetic disorder, recently described as presenting an incidence rate ranging from 0.38 to 1.09 per 100,000 live male births, and it is the only X-linked-inherited mucopolysaccharidosis. The complex disease is due to a deficit of the lysosomal hydrolase iduronate 2-sulphatase, which is a crucial enzyme in the stepwise degradation of heparan and dermatan sulphate.
    [Show full text]
  • Tepzz¥5Z5 8 a T
    (19) TZZ¥Z___T (11) EP 3 505 181 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 03.07.2019 Bulletin 2019/27 A61K 38/46 (2006.01) C12N 9/16 (2006.01) (21) Application number: 18248241.4 (22) Date of filing: 28.12.2018 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • DICKSON, Patricia GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Torrance, CA California 90502 (US) PL PT RO RS SE SI SK SM TR • CHOU, Tsui-Fen Designated Extension States: Torrance, CA California 90502 (US) BA ME • EKINS, Sean Designated Validation States: Brooklyn, NY New York 11215 (US) KH MA MD TN • KAN, Shih-Hsin Torrance, CA California 90502 (US) (30) Priority: 28.12.2017 US 201762611472 P • LE, Steven 05.04.2018 US 201815946505 Torrance, CA California 90502 (US) • MOEN, Derek R. (71) Applicants: Torrance, CA California 90502 (US) • Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (74) Representative: J A Kemp Torrance, CA 90502 (US) 14 South Square • Phoenix Nest Inc. Gray’s Inn Brooklyn NY 11215 (US) London WC1R 5JJ (GB) (54) PREPARATION OF ENZYME REPLACEMENT THERAPY FOR MUCOPOLYSACCHARIDOSIS IIID (57) The present disclosure relates to compositions for use in a method of treating Sanfilippo syndrome (also known as Sanfilippo disease type D, Sanfilippo D, mu- copolysaccharidosis type IIID, MPS IIID). The method can entail injecting to the spinal fluid of a MPS IIID patient an effective amount of a composition comprising a re- combinant human acetylglucosamine-6-sulfatase (GNS) protein comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 and having the en- zymatic activity of the human GNS protein.
    [Show full text]
  • Sanfilippo Disease Type D: Deficiency of N-Acetylglucosamine-6- Sulfate Sulfatase Required for Heparan Sulfate Degradation
    Proc. Nat!. Acad. Sci. USA Vol. 77, No. 11, pp. 6822-6826, November 1980 Medical Sciences Sanfilippo disease type D: Deficiency of N-acetylglucosamine-6- sulfate sulfatase required for heparan sulfate degradation (mucopolysaccharidosis/keratan sulfate/lysosomes) HANS KRESSE, EDUARD PASCHKE, KURT VON FIGURA, WALTER GILBERG, AND WALBURGA FUCHS Institute of Physiological Chemistry, Waldeyerstrasse 15, D-4400 Mfinster, Federal Republic of Germany Communicated by Elizabeth F. Neufeld, July 10, 1980 ABSTRACT Skin fibroblasts from two patients who had lippo syndromes and excreted excessive amounts of heparan symptoms of the Sanfilippo syndrome (mucopolysaccharidosis sulfate and keratan sulfate in the urine. His fibroblasts were III) accumulated excessive amounts of hean sulfate and were unable to desulfate N-acetylglucosamine-6-sulfate and the unable to release sulfate from N-acety lucosamine)--sulfate linkages in heparan sulfate-derived oligosaccharides. Keratan corresponding sugar alcohol (17, 18). It was therefore suggested sulfate-derived oligosaccharides bearing the same residue at that N-acetylglucosamine-6-sulfate sulfatase is involved in the the nonreducing end and p-nitrophenyl6sulfo-2-acetamido- catabolism of both types of macromolecules. 2-deoxy-D-ucopyranoside were degraded normally. Kinetic In this paper, we describe a new disease, tentatively desig- differences between the sulfatase activities of normal fibro- nated Sanfilippo disease type D, that is characterized by the blasts were found. These observations suggest that N-acetyl- excessive excretion glucosamine4-6sulfate sulfatase activities degrading heparan clinical features of the Sanfilippo syndrome, sulfate and keratan sulfate, respectively, can be distinguished. of heparan sulfate, and the inability to release inorganic sulfate It is the activity directed toward heparan sulfate that is deficient from N-acetylglucosamine-6-sulfate residues of heparan sul- in these patients; we propose that this deficiency causes Sanfi- fate-derived oligosaccharides.
    [Show full text]
  • Journal of Inborn Errors of Metabolism & Screening
    Original Article Journal of Inborn Errors Determination of Reference Values for of Metabolism & Screening 2021, Volume 9: e20200023 Alpha-N-Acetylglucosaminidase Activities DOI: https://doi.org/10.1590/2326–4594– JIEMS–2020–0023 in Patients with Sanfilippo Type B Disease and Control Population in Colombia Johana Ramírez Borda1 and Alfredo Uribe-Ardila1 Abstract Sanfilippo B is a lysosomal disorder characterized by the pathological accumulation of heparan sulfate. It is caused by mutations in the NAGLU gene that codes for the alpha-N-acetylglucosaminidase enzyme. The objective of this study was to determine the reference values and frequency of Sanfilippo B in Colombia through an enzyme analysis of leukocytes extracts. We aim to inform the community and the health system so that they can work in a preventive way, providing an early diagnosis of patients and thus providing an appropriate management of the symptoms. We carried out an endpoint assay that indirectly quantifies NAGLU activity through the cleavage of 4-methylumbelliferone from the 4-methylumbelliferyl-2-acetamido-2-deoxy-α-D-glucopyranoside substrate. The activity of 463 healthy volunteers (Range: 0.6 - 4 nmol/mg/h , Median: 1.69 +/- 0.73 ) as well as 462 patients referred for clinical suspicion, was calculated. From the last group, 7 cases turned out to be positive (Range: 0 - 0.24 nmol/mg/h , Median: 0.13 +/- 0.09 ). The cut-off point according to ROC analysis between affected patients and controls was 0.42 nmol/mg/h. To our knowledge, this study is the first in Colombia where an estimated frequency of Sanfilippo type B is calculated by providing enzyme activity ranges and a cut-off point.
    [Show full text]
  • Anesthetic Considerations and Clinical Manifestations 243
    MUCOPOLYSACCHARIDOSES: ANESTHETIC CONSIDERATIONS AND CLINICAL MANIFESTATIONS 243 MUCOPOLYSACCHARIDOSES: ANESTHETIC CONSIDERATIONS AND CLINICAL MANIFESTATIONS * ** *** JERMALE A. SAM , AMIR R. BALUCH , RASHID S. NIAZ , *** **** LINDSEY LONADIER AND ALAN D. KAYE Abstract Mucopolysaccharidosis (MPS) is a group of genetic disorders that presents challenges during anesthetic care and in particular difficulty with airway management. Patients should be managed by experienced anesthesiologists at centers that are familiar with these types of conditions. Rarely encountered disease states have been identified as important topics in the continuing education of clinical anesthesiologists. This review will define MPS, describe the pathophysiology of MPS, describe how patients with this rare lysosomal storage disorders have dysfunction of tissues, cite the incidence of MPS, list the clinical manifestations and specific problems associated with the administration of anesthesia to patients with MPS, present treatment options for patients with MPS, define appropriate preoperative evaluation and perioperative management of these patients, including, to anticipate potential postoperative airway problems. Introduction Mucopolysaccharidoses (MPS) are a group of rare genetic lysosomal storage disorders characterized by the deficiency in or complete lack of necessary lysosomal enzymes required for the stepwise breakdown of glycosaminoglycans (GAGs, also known as mucopolysaccharidoses)1-5. Consequently, fragments of GAGs accumulate intracellularly in the lysosome resulting in cellular enlargement causing disruption/dysfunction of structure and function of tissues. This process leads to numerous clinical abnormalities. Incidence of all types of MPS is reported to be between 1in 10,000 to 1 in 30,000 live births and are transmitted autosomal recessive except for MPS II which is X-linked1,4,5. Pathophysiology Glycosaminoglycans are long-chain complex carbohydrates consisting of repeating sulfated acidic and amino sugar disaccharide units.
    [Show full text]
  • Sanfilippo Type B Syndrome (Mucopolysaccharidosis III B)
    European Journal of Human Genetics (1999) 7, 34–44 t © 1999 Stockton Press All rights reserved 1018–4813/99 $12.00 http://www.stockton-press.co.uk/ejhg ARTICLES Sanfilippo type B syndrome (mucopolysaccharidosis III B): allelic heterogeneity corresponds to the wide spectrum of clinical phenotypes Birgit Weber1, Xiao-Hui Guo1, Wim J Kleijer2, Jacques JP van de Kamp3, Ben JHM Poorthuis4 and John J Hopwood1 1Lysosomal Diseases Research Unit, Department of Chemical Pathology, Women’s and Children’s Hospital, North Adelaide, Australia 2Department of Clinical Genetics, University Hospital, Rotterdam 3Leiden University Medical Centre, Leiden 4University of Leiden, Department of Pediatrics, Leiden, The Netherlands Sanfilippo B syndrome (mucopolysaccharidosis IIIB, MPS IIIB) is caused by a deficiency of α-N-acetylglucosaminidase, a lysosomal enzyme involved in the degradation of heparan sulphate. Accumulation of the substrate in lysosomes leads to degeneration of the central nervous system with progressive dementia often combined with hyperactivity and aggressive behaviour. Age of onset and rate of progression vary considerably, whilst diagnosis is often delayed due to the absence of the pronounced skeletal changes observed in other mucopolysaccharidoses. Cloning of the gene and cDNA encoding α-N-acetylglucosaminidase enabled a study of the molecular basis of this syndrome. We were able to identify 31 mutations, 25 of them novel, and two polymorphisms in the 40 patients mostly of Australasian and Dutch origin included in this study. The observed allellic heterogeneity reflects the wide spectrum of clinical phenotypes reported for MPS IIIB patients. The majority of changes are missense mutations; also four nonsense and nine frameshift mutations caused by insertions or deletions were identified.
    [Show full text]
  • Sanfilippo Type C Diagnosis: Assay of Acetyl- Coa: A-Glucosaminide N-Acetyltransferase Using [14C]Glucosamineas Substrate and Leukocytes As Enzyme Source
    CYSTIC FIBROSIS 543 12. McNeely, M. C., Awasthi, Y. C., Barnett, D. R., Iwasumi, T., Schneider, L., factor in patients with cystic fibrosis of the pancreas. Pediatr. Res., 1: 173 Srivastava, S. K., and Bowman B. H.: Cystic fibrosis. 11. The urinary (1967). mucociliary inhibitor. Pediatr. Res., 16: 21 (1982). 17. Wilson, G. B., and Fudenberg, H. H.: Studies on cystic fibrosis using isoelectric 13. Neufeld, E. F. and Ashwell, G.: Carbohydrate recognition systems for receptor- focusing. IV. Distinction between ciliary dyskinesia activity in cystic fibrosis mediated pinocytosis. In: W. J. Lennarz: The Biochemistry of Glycoproteins and asthmatic sera and association of cystic fibrosis protein with the activity and Proteoglycans. p. 241 (Plenum Press, New York, 1980). in cystic fibrosis serum. Pediatr. Res., 11: 317 (1977). 14. Sly, W. S.: Saccharide traffic signals in receptor-mediated endocytosis and 18. We thank Dr. Kurt Hirschhorn for his stimulating discussions and suggestions. transport of acid hydrolases. In: L. Svennerholm, P. Mandel, H. Dreyfus, We also thank Mr. James Miller for his skillful, technical assistance. P.-F. Urban: Structure and Function of Gangliosides. p. 433 (Plenum Press, 19. Requests for reprints should be addressed to: Dr Emmanuel Shapira, Head, New York, 1980). Sections of Clinical and Biochemical Genetics, Tulane University School of 15. Spiro, R. G.: Study of the carbohydrates of glycoproteins. In: V. Ginsburg: Medicine, 1430 Tulane Avenue, New Orleans, Louisiana 701 12. Methods in Enzymology. Vol. XXVIII. p. 3 (Academic Press, New York, 20. This study was supported in part by a grant from the Hayward Foundation. 1972). 2 1. Received for publication November 30, 1982.
    [Show full text]
  • Mucopolysaccharidosis: Caregiver Quality of Life
    Original Article Journal of Inborn Errors of Metabolism &Screening 1–7 Mucopolysaccharidosis: Caregiver ª The Author(s) 2015 Reprints and permission: Quality of Life sagepub.com/journalsPermissions.nav DOI: 10.1177/2326409815613804 iem.sagepub.com Nicole Ruas Guarany, PhD1,2, Ana Paula Vanz, MD3, Matheus Vernet Machado Bressan Wilke4, Daniele Dorneles Bender5, Mariana Dumer Borges5, Roberto Giugliani, PhD6,7, and Ida Vanessa Doederlein Schwartz, PhD1,6,7 Abstract The mucopolysaccharidoses (MPSs) are a group of rare genetic diseases caused by a deficiency of specific enzymes involved in catabolism of glycosaminoglycans, which causes multisystem abnormalities. Quality of life (QoL) is directly associated with physical, mental, and psychological well-being and with social relationships, including family and friends. Aims: To evaluate the QoL of caregivers of patients with MPS. Methods: Cross-sectional study using a convenience sampling strategy. The sample comprised mothers of patients with MPS seen at the Medical Genetics Service, Hospital de Clı´nicas de Porto Alegre, Brazil. The World Health Organization Quality of Life Assessment (WHOQOL-BREF) was used to assess QoL. Results: Eleven mothers of 12 patients with MPS (MPS-I ¼ 1; MPS-II ¼ 3; MPS-III ¼ 3; MPS-IV ¼ 4; and MPS-VI ¼ 1) were included. The average WHOQOL-BREF score was 46.59, with the physical health domain scoring highest and the environmental domain scoring lowest. The lower QoL of mothers of children with MPS-II seems to be related to the worse clinical condition of these children, with more severe symptoms and greater need for help with daily activities as well as with a feeling of responsibility due to the inheritance pattern of the disease.
    [Show full text]
  • RARE Foundation Alliance List RARE Hub 2021-08
    The Global Genes RARE Foundation Alliance is made up of over 750 disease foundations that have committed to collaborating with Global Genes and other nonprofit foundations in order to create a stronger, collective voice in the rare disease community. #Bold Lips For Sickle Cell – Sickle Cell Disease 11q Research & Resource Group – Jacobsen Syndrome, 11q Chromosome 1p36 Deletion Support & Awareness – 1p36 Deletion Syndrome 22q 11 Ireland support group – 22q11.2 deletion syndrome 4p- Support Group – Wolf-Hirschhorn Syndrome and related 4p conditions 5p-Society– 5p- Syndrome, Cat Cry Syndrome, Cri du Chat Syndrome 17q12 Foundation - 17q12 Deletions and Duplications A Breath Of Hope Foundation For NMO - Neuromyelitis Optica A Foundation Building Strength for Nemaline Myopathy – Nemaline Myopathy A Nonprofit Group Enriching Lives (ANGEL AID) - Multiple rare diseases Aaron’s Ohtahara – Ohtahara Syndrome Acid Maltase Deficiency Association– Acid Maltase Deficiency, Pompe’s Disease Acromegaly Community – Acromegaly and Gigantism Acromegaly Ottawa Awareness & Support Network - Acromegaly Acoustic Neuroma Association – Acoustic Neuroma ADCY5.org – ADCY5 Mutation Addi & Cassi Fund – Niemann Pick Type C ADNPkids – ADNP Syndrome, Helsmoortal_Van Der AA Syndrome Adrenal Alternatives Foundation - Adrenal Diseases Adrenal Insufficiency United – Adrenal Insufficiency Adult Polyglucosan Body Disease Research Foundation (APBDRF) – APBD Advancing Sickle Cell Advocacy Project, Inc. – Sickle Cell Disease Advocacy & Awareness for Immune Disorders Association – Primary
    [Show full text]
  • Mortality in Patients with Sanfilippo Syndrome Christine Lavery1*, Chris J
    Lavery et al. Orphanet Journal of Rare Diseases (2017) 12:168 DOI 10.1186/s13023-017-0717-y RESEARCH Open Access Mortality in patients with Sanfilippo syndrome Christine Lavery1*, Chris J. Hendriksz2 and Simon A. Jones3 Abstract Background: Sanfilippo syndrome (mucopolysaccharidosis type III; MPS III) is an inherited monogenic lysosomal storage disorder divided into subtypes A, B, C and D. Each subtype is characterized by deficiency of a different enzyme participating in metabolism of heparan sulphate. The resultant accumulation of this substrate in bodily tissues causes various malfunctions of organs, ultimately leading to premature death. Eighty-four, 24 and 5 death certificates of patients with Sanfilippo syndrome types A, B and C, respectively, were obtained from the Society of Mucopolysaccharide Diseases (UK) to better understand the natural course of these conditions, covering the years 1977–2007. Results: In Sanfilippo syndrome type A mean age at death (± standard deviation) was 15.22 ± 4.22 years, 18.91 ± 7. 33 years for patients with Sanfilippo syndrome type B and 23.43 ± 9.47 years in Sanfilippo syndrome type C. Patients with Sanfilippo syndrome type A showed significant increase in longevity over the period of observation (p =0.012). Survival rates of patients with Sanfilippo syndrome type B did not show a statistically significant improvement (p =0. 134). In Sanfilippo syndrome types A and B, pneumonia was identified as the leading cause of death. Conclusions: The analysis of 113 death certificates of patients with Sanfilippo syndrome in the UK has demonstrated that the longevity has improved significantly in patients with Sanfilippo syndrome type A over a last few decades.
    [Show full text]
  • Global Genes RARE Foundation Alliance Is Made up of More Than
    Global Genes RARE Foundation Alliance is made up of more than 500 disease foundations that are committed to collaborating with Global Genes and other nonprofit foundations in order to create a stronger, collective voice in the rare disease community. #11q Research & Resource Group – Jacobsen Syndrome, 11q Chromosome 1p36 Deletion Support & Awareness – 1p36 Deletion Syndrome 4p- Support Group – Wolf-Hirschhorn Syndrome and related 4p conditions 5p-Society– 5p- Syndrome, Cat Cry Syndrome, Cri du Chat Syndrome A Foundation Building Strength for Nemaline Myopathy – Nemaline Myopathy Aaron’s Ohtahara – Ohtahara Syndrome Acid Maltase Deficiency Association– Acid Maltase Deficiency, Pompe’s Disease Acromegaly Community – Acromegaly and Gigantism Acoustic Neuroma Association – Acoustic Neuroma ADCY5.org – ADCY5 Mutation Addi & Cassi Fund – Niemann Pick Type C ADNPkids – ADNP Syndrome, Helsmoortal_Van Der AA Syndrome Adrenal Insufficiency United – Adrenal Insufficiency Adult Polyglucosan Body Disease Research Foundation (APBDRF) – APBD Advancing Sickle Cell Advocacy Project, Inc. – Sickle Cell Disease Advocacy & Awareness for Immune Disorders Association – Primary Immunodeficiency Diseases (PIDD), Hereditary Angioedema, Pediatric Acute onset Neuropsychiatric Syndrome (PANS), Autoimmune diseases AHC Federation of Europe – Alternating Hemiplegia of Childhood Aicardi-Goutieres Syndrome Association of the Americas (AGSAA)- Aicardi-Goutieres Syndrome Aidan Jack Seeger Foundation – Adrenoleukodystrophy AKU Society – Alkaptonuria AKU Society North America
    [Show full text]